Hims & Hers Health (HIMS) Set to Announce Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is scheduled to post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect Hims & Hers Health to post earnings of $0.02 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million during the quarter, compared to analysts’ expectations of $245.84 million. During the same period last year, the business earned ($0.05) earnings per share. The firm’s revenue was up 47.4% on a year-over-year basis. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $11.26 on Friday. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $17.16. The firm has a market cap of $2.41 billion, a P/E ratio of -102.36 and a beta of 0.97. The firm’s 50-day simple moving average is $14.01 and its 200 day simple moving average is $10.25.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HIMS. Canaccord Genuity Group began coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price on the stock. Leerink Partnrs restated a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Seaport Res Ptn reiterated a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Citigroup upped their price target on shares of Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, SVB Leerink began coverage on shares of Hims & Hers Health in a research note on Monday, February 26th. They issued a “market perform” rating and a $10.00 price objective on the stock. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.85.

Insider Activity

In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the transaction, the insider now directly owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 736,191 shares of company stock worth $9,733,700. 31.63% of the stock is currently owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.